Evommune, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
EVMN New York 2834 www.evommune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Evommune, Inc.

Evommune’s stock rallies 70% on Phase IIa eczema data - Feb 11th, 2026 5:53 am
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill - Feb 11th, 2026 2:33 am
Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. - Feb 10th, 2026 2:07 pm
Sector Update: Health Care Stocks Mixed Late Afternoon - Feb 10th, 2026 1:43 pm
Top Midday Gainers - Feb 10th, 2026 12:18 pm
Sector Update: Health Care Stocks Mixed Tuesday Afternoon - Feb 10th, 2026 11:45 am
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis - Feb 10th, 2026 5:30 am
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 - Jan 19th, 2026 9:28 am
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Dec 11th, 2025 2:05 pm
Carvana initiated, Zscaler downgraded: Wall Street's top analyst calls - Dec 1st, 2025 7:46 am
NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading - Nov 6th, 2025 6:55 am
Evommune Announces Pricing of its Initial Public Offering - Nov 5th, 2025 5:45 pm
Evommune Announces Commencement of Initial Public Offering - Oct 30th, 2025 4:30 am